Internal Medicine Department, Hackensack University Medical Center, Hackensack, New Jersey, USA,
Third Faculty of Medicine, Charles University, Prague, Czechia,
Kidney Blood Press Res. 2023;48(1):347-356. doi: 10.1159/000530803. Epub 2023 Apr 25.
The main objective of this study was to identify the best combination of admission day parameters for predicting COVID-19 mortality in hospitalized patients. Furthermore, we sought to compare the predictive capacity of pulmonary parameters to that of renal parameters for mortality from COVID-19.
In this retrospective study, all patients admitted to a tertiary hospital between September 1st, 2020, and December 31st, 2020, who were clinically symptomatic and tested positive for COVID-19, were included. We gathered extensive data on patient admissions, including laboratory results, comorbidities, chest X-ray (CXR) images, and SpO2 levels, to determine their role in predicting mortality. Experienced radiologists evaluated the CXR images and assigned a score from 0 to 18 based on the severity of COVID-19 pneumonia. Further, we categorized patients into two independent groups based on their renal function using the RIFLE and KDIGO criteria to define the acute kidney injury (AKI) and chronic kidney disease (CKD) groups. The first group ("AKI&CKD") was subdivided into six subgroups: normal renal function (A); CKD grade 2+3a (B); AKI-DROP (C); CKD grade 3b (D); AKI-RISE (E); and grade 4 + 5 CKD (F). The second group was based only on estimated glomerular filtration rate (eGFR) at the admission, and thus it was divided into four grades: grade 1, grade 2+3a, grade 3b, and grade 4 + 5.
The cohort comprised 619 patients. Patients who died during hospitalization had a significantly higher mean radiological score compared to those who survived, with a p value <0.01. Moreover, we observed that the risk for mortality was significantly increased as renal function deteriorated, as evidenced by the AKI&CKD and eGFR groups (p < 0.001 for each group). Regarding mortality prediction, the area under the curve (AUC) for renal parameters (AKI&CKD group, eGFR group, and age) was found to be superior to that of pulmonary parameters (age, radiological score, SpO2, CRP, and D-dimer) with an AUC of 0.8068 versus 0.7667. However, when renal and pulmonary parameters were combined, the AUC increased to 0.8813. Optimal parameter combinations for predicting mortality from COVID-19 were identified for three medical settings: Emergency Medical Service (EMS), the Emergency Department, and the Internal Medicine Floor. The AUC for these settings was 0.7874, 0.8614, and 0.8813, respectively.
Our study demonstrated that selected renal parameters are superior to pulmonary parameters in predicting COVID-19 mortality for patients requiring hospitalization. When combining both renal and pulmonary factors, the predictive ability of mortality significantly improved. Additionally, we identified the optimal combination of factors for mortality prediction in three distinct settings: EMS, Emergency Department, and Internal Medicine Floor.
本研究的主要目的是确定入院当天参数的最佳组合,以预测住院患者的 COVID-19 死亡率。此外,我们还试图比较肺参数和肾参数对 COVID-19 死亡率的预测能力。
在这项回顾性研究中,纳入了 2020 年 9 月 1 日至 12 月 31 日期间在一家三级医院住院且临床症状明显并经 COVID-19 检测呈阳性的所有患者。我们收集了大量患者入院数据,包括实验室结果、合并症、胸部 X 线(CXR)图像和 SpO2 水平,以确定它们在预测死亡率方面的作用。有经验的放射科医生根据 COVID-19 肺炎的严重程度,对 CXR 图像进行评估,并根据严重程度从 0 到 18 分进行评分。此外,我们根据肾脏功能使用 RIFLE 和 KDIGO 标准将患者分为两组,将患者分为两个独立的组,以定义急性肾损伤(AKI)和慢性肾脏病(CKD)组。第一组(“AKI&CKD”)进一步分为六个亚组:肾功能正常(A);CKD 2+3a 级(B);AKI-DROP(C);CKD 3b 级(D);AKI-RISE(E);和 4+5 级 CKD(F)。第二组仅基于入院时的估计肾小球滤过率(eGFR),因此分为四级:1 级、2+3a 级、3b 级和 4+5 级。
该队列包括 619 名患者。与存活患者相比,住院期间死亡的患者的平均放射评分明显更高,p 值 <0.01。此外,我们观察到随着肾功能恶化,死亡率显著增加,这一点在 AKI&CKD 和 eGFR 组中得到了证明(每组 p < 0.001)。关于死亡率预测,发现肾参数(AKI&CKD 组、eGFR 组和年龄)的曲线下面积(AUC)优于肺参数(年龄、放射评分、SpO2、CRP 和 D-二聚体),AUC 为 0.8068 比 0.7667。然而,当合并肾和肺参数时,AUC 增加到 0.8813。确定了三种医疗环境下 COVID-19 死亡率预测的最佳参数组合:急诊医疗服务(EMS)、急诊室和内科病房。这些环境的 AUC 分别为 0.7874、0.8614 和 0.8813。
我们的研究表明,与需要住院的患者的肺参数相比,选定的肾参数在预测 COVID-19 死亡率方面更具优势。当合并肾和肺因素时,死亡率预测的预测能力显著提高。此外,我们在 EMS、急诊室和内科病房三个不同的环境中确定了死亡率预测的最佳因素组合。